Wells Fargo’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $232 | Buy |
115
+78
| +211% | +$175 | ﹤0.01% | 6453 |
|
|
2025
Q4 | $60 | Hold |
37
| – | – | ﹤0.01% | 6494 |
|
|
2025
Q3 | $40 | Sell |
37
-20
| -35% | -$22 | ﹤0.01% | 6542 |
|
|
2025
Q2 | $66 | Hold |
57
| – | – | ﹤0.01% | 6536 |
|
|
2025
Q1 | $53 | Sell |
57
-40
| -41% | -$40 | ﹤0.01% | 6447 |
|
|
2024
Q4 | $83 | Sell |
97
-47
| -33% | -$66 | ﹤0.01% | 6435 |
|
|
2024
Q3 | $239 | Sell |
144
-27
| -16% | -$47 | ﹤0.01% | 6218 |
|
|
2024
Q2 | $275 | Sell |
171
-96
| -36% | -$194 | ﹤0.01% | 6186 |
|
|
2024
Q1 | $612 | Sell |
267
-53
| -17% | -$123 | ﹤0.01% | 6245 |
|
|
2023
Q4 | $720 | Sell |
320
-10
| -3% | -$24 | ﹤0.01% | 6308 |
|
|
2023
Q3 | $996 | Sell |
330
-25
| -7% | -$95 | ﹤0.01% | 6203 |
|
|
2023
Q2 | $1.46K | Sell |
355
-53
| -13% | -$208 | ﹤0.01% | 6262 |
|
|
2023
Q1 | $1.53K | Hold |
408
| – | – | ﹤0.01% | 6277 |
|
|
2022
Q4 | $2.28K | Sell |
408
-78
| -16% | -$459 | ﹤0.01% | 5979 |
|
|
2022
Q3 | $2K | Buy |
486
+55
| +13% | +$445 | ﹤0.01% | 6205 |
|
|
2022
Q2 | $5K | Sell |
431
-5,090
| -92% | -$48.6K | ﹤0.01% | 6030 |
|
|
2022
Q1 | $105K | Sell |
5,521
-2,501
| -31% | -$39.3K | ﹤0.01% | 5303 |
|
|
2021
Q4 | $142K | Sell |
8,022
-7,274
| -48% | -$218K | ﹤0.01% | 5458 |
|
|
2021
Q3 | $568K | Buy |
15,296
+9,575
| +167% | +$425K | ﹤0.01% | 4596 |
|
|
2021
Q2 | $341K | Buy |
5,721
+3,448
| +152% | +$209K | ﹤0.01% | 4806 |
|
|
2021
Q1 | $152K | Sell |
2,273
-8,390
| -79% | -$657K | ﹤0.01% | 5289 |
|
|
2020
Q4 | $645K | Buy |
10,663
+7,379
| +225% | +$504K | ﹤0.01% | 4348 |
|
|
2020
Q3 | $259K | Sell |
3,284
-1,629
| -33% | -$130K | ﹤0.01% | 4811 |
|
|
2020
Q2 | $307K | Buy |
4,913
+575
| +13% | +$33.5K | ﹤0.01% | 4658 |
|
|
2020
Q1 | $230K | Buy |
4,338
+415
| +11% | +$41.1K | ﹤0.01% | 4599 |
|
|
2019
Q4 | $475K | Sell |
3,923
-303
| -7% | -$43.6K | ﹤0.01% | 4422 |
|
|
2019
Q3 | $766K | Buy |
4,226
+172
| +4% | +$24.2K | ﹤0.01% | 4047 |
|
|
2019
Q2 | $526K | Sell |
4,054
-248
| -6% | -$44.5K | ﹤0.01% | 4344 |
|
|
2019
Q1 | $1.05M | Buy |
4,302
+43
| +1% | +$11.4K | ﹤0.01% | 3842 |
|
|
2018
Q4 | $811K | Sell |
4,259
-635
| -13% | -$155K | ﹤0.01% | 4002 |
|
|
2018
Q3 | $1.6M | Buy |
4,894
+540
| +12% | +$165K | ﹤0.01% | 3580 |
|
|
2018
Q2 | $1.36M | Buy |
4,354
+652
| +18% | +$199K | ﹤0.01% | 3768 |
|
|
2018
Q1 | $902K | Sell |
3,702
-167
| -4% | -$46.8K | ﹤0.01% | 3992 |
|
|
2017
Q4 | $1.17M | Sell |
3,869
-487
| -11% | -$136K | ﹤0.01% | 3826 |
|
|
2017
Q3 | $1.15M | Buy |
4,356
+520
| +14% | +$150K | ﹤0.01% | 3746 |
|
|
2017
Q2 | $1.01M | Sell |
3,836
-1,538
| -29% | -$385K | ﹤0.01% | 3720 |
|
|
2017
Q1 | $1.94M | Sell |
5,374
-1,553
| -22% | -$481K | ﹤0.01% | 3232 |
|
|
2016
Q4 | $2M | Buy |
6,927
+2,035
| +42% | +$631K | ﹤0.01% | 3152 |
|
|
2016
Q3 | $1.67M | Sell |
4,892
-315
| -6% | -$115K | ﹤0.01% | 3106 |
|
|
2016
Q2 | $2.21M | Sell |
5,207
-37
| -0.7% | -$15.2K | ﹤0.01% | 2896 |
|
|
2016
Q1 | $1.68M | Buy |
5,244
+1,742
| +50% | +$594K | ﹤0.01% | 3050 |
|
|
2015
Q4 | $1.82M | Buy |
3,502
+1,048
| +43% | +$387K | ﹤0.01% | 3049 |
|
|
2015
Q3 | $719K | Buy |
2,454
+1,504
| +158% | +$535K | ﹤0.01% | 3720 |
|
|
2015
Q2 | $373K | Buy |
950
+687
| +261% | +$242K | ﹤0.01% | 4267 |
|
|
2015
Q1 | $79K | Sell |
263
-289
| -52% | -$70.5K | ﹤0.01% | 4840 |
|
|
2014
Q4 | $123K | Sell |
552
-221
| -29% | -$45.6K | ﹤0.01% | 4663 |
|
|
2014
Q3 | $179K | Buy |
773
+610
| +374% | +$154K | ﹤0.01% | 4402 |
|
|
2014
Q2 | $36K | Buy |
+163
| New | +$36.3K | ﹤0.01% | 5097 |
|
|
2013
Q4 | – | Sell |
-198
| Closed | -$29K | – | 5928 |
|
|
2013
Q3 | $29K | Sell |
198
-6
| -3% | -$725 | ﹤0.01% | 4851 |
|
|
2013
Q2 | $31K | Buy |
+204
| New | +$27.9K | ﹤0.01% | 4748 |
|
Other funds holding TXMD
RCMNY
CC
SCM
VCM
TC
ACM
Wells Fargo's TXMD Position: Q1 2026 in Review
Wells Fargo increased its TherapeuticsMD (TXMD) stake by 211% in Q1 2026, buying an estimated $175 and bringing the position to 115 shares worth $232. The position accounts for ﹤0.01% of the portfolio, ranked #6453.
Wells Fargo first reported a position in TXMD in Q2 2013 and has held it in 50 quarters since. The position peaked at $2.21M in Q2 2016. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.
- Wells Fargo held 115 shares of TherapeuticsMD worth $232 as of Q1 2026.
- Wells Fargo bought 78 TherapeuticsMD shares in Q1 2026, an estimated $175.
- TherapeuticsMD made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6453 holding.
- Wells Fargo first reported a position in TherapeuticsMD in Q2 2013 and has held it in 50 quarters since.
- Wells Fargo's TherapeuticsMD position peaked at $2.21M in Q2 2016.
- 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.